Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Key facts
- Who runs it
- Takeda
- Where
- Ann Arbor, Atlanta, Baltimore, Birmingham, Boston, Charleston, Cleveland, Colorado Springs, Denison, Escondido, Gainesville, Hershey, Houston, Indianapolis, Iowa City, La Jolla, Los Angeles, Miami, Nashville, New Orleans, New York, Novi, Palo Alto, Philadelphia, Phoenix, Richmond, Rochester, San Antonio, San Francisco, St Louis, and Tucson, United StatesSee the 37 sitesAlso in 18 other countries, 53 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 160 people, planned
- Started
- 6 Mar 2023
- Expected to end
- 12 Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Fazirsiran Injection
- Placebo
- Record updated
- 13 May 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- The participant must have a diagnosis of the Z allele homozygotes (PiZZ) genotype AATD. PiZZ diagnosis from source verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted
- The participant, of any sex, is aged 18 to 75 years, inclusive
- The participant's liver biopsy core sample collected should meet the requirements of the protocol
- The participant has evidence of METAVIR stage F2, F3, or F4 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading of a previous biopsy conducted within 6 months before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual
- The participant has a pulmonary status meeting the protocol's requirements
- It must be confirmed that the participant does not have HCC. Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced CT or MRI imaging to exclude HCC before randomization
- An adult participant must have a body mass index (BMI) greater than or equal to (>=) 18.0 kilograms per meter square (kg\^m2)
- The participant is a nonsmoker for at least 6 months before screening
Who cannot take part
- The participant has a history of the presence of medium or large varices or varices with red wale signs based on a previous esophagogastroduodenoscopy (EGD) within 6 months before the estimated enrollment date. For certain participants, an EGD will be required at screening if there is no EGD available within 6 months before the estimated enrollment date. Presence of small varices with no red wale signs on EGD and no history of bleeding will be acceptable for study eligibility
- The participant has previously been treated with fazirsiran or any other RNAi for AATD-LD
- The participant has a prior transjugular portosystemic shunt procedure
- The participant has a history of liver decompensating events (overt hepatic encephalopathy [West Haven Grade >=2] documented by a physician or healthcare professional, clinically significant ascites, spontaneous bacterial peritonitis, GI bleeding from varices, hepatopulmonary syndrome, hepatorenal syndrome, portal pulmonary hypertension, or bleeding portal hypertensive gastropathy)
- The participant has evidence of chronic liver disease attributable to other diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis
- The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening
- The participant has portal vein thrombosis
- The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with other curatively treated malignancies who have no evidence of metastatic disease and a greater than 1-year disease-free interval may be entered after approval by the medical monitor
- The participant has alanine transaminase (ALT) or aspartate transaminase (AST) levels >250 units per liter (U/L)
- The participant has a platelet count <60,000 per cubic millimeter (mm\^3) (<60 × 10\^9 per liter [10\^9/L])
- The participant has albumin <=2.8 gram per deciliter (g/dL) (28 grams per liter [g/L])
- The participant has international normalized ratio (INR) >=1.7
- The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 18 other countries, 53 sites
- University of Michigan HospitalAnn Arbor, United StatesContact: Robert Fontana (principal investigator)Taking people
- Children's Healthcare of AtlantaAtlanta, United StatesNo longer taking part
- University of Maryland Medical CenterBaltimore, United StatesContact: Kirti Shetty (principal investigator)Taking people
- University of Alabama at BirminghamBirmingham, United StatesContact: Meagan Gray (principal investigator)Taking people
- Boston Medical CenterBoston, United StatesContact: Arpan Mohanty (principal investigator)Taking people
- Brigham and Womens HospitalBoston, United StatesContact: Nikroo Hashemi (principal investigator)Taking people
- Medical University of South CarolinaCharleston, United StatesContact: Charlie Strange (principal investigator)Taking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Seth Sclair (principal investigator)Taking people
- Peak Gastroenterology Associates, PCColorado Springs, United StatesContact: Bhaktasharan Patel (principal investigator)Taking people
- Texoma Liver CenterDenison, United StatesContact: Hesham Elgouhari (principal investigator)Taking people
- Gastroenterology & Liver InstituteEscondido, United StatesNo longer taking part
- University of FloridaGainesville, United StatesContact: Virginia Clark (principal investigator)Taking people
- Penn State Health Milton S. Hershey Medical CenterHershey, United StatesContact: Timothy Craig (principal investigator)Taking people
- Baylor College of Medicine Medical CenterHouston, United StatesContact: George Cholankeril (principal investigator)Taking people
- Indiana University School of Medicine - IndianapolisIndianapolis, United StatesContact: Raj Vuppalanchi (principal investigator)Taking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Tomohiro Tanaka (principal investigator)Taking people
- University of California San Diego, Altman Clinical and Translational InstituteLa Jolla, United StatesContact: Rohit Loomba (principal investigator)Taking people
- UCLA Pulmonary and Critical CareLos Angeles, United StatesContact: Igor Barjaktarevic (principal investigator)Taking people
- Schiff Center for Liver Diseases/University of MiamiMiami, United StatesContact: Eugene Schiff (principal investigator)Taking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Roman Perri (principal investigator)Taking people
- Ochsner Medical CenterNew Orleans, United StatesContact: George Therapondos (principal investigator)Taking people
- Columbia University Irving Medical CenterNew York, United StatesContact: Monica Goldklang (principal investigator)Taking people
- NYU Langone HealthNew York, United StatesContact: Viviana Figueroa Diaz (principal investigator)Taking people
- Morgan Stanley Childrens Hospital of New York Presbyterian (CHONY) - PINNew York, United StatesNo longer taking part
- Henry Ford Medical Center-ColumbusNovi, United StatesContact: Stuart Gordon (principal investigator)Taking people
- Stanford UniversityPalo Alto, United StatesContact: Paul Kwo (principal investigator)Taking people
- Temple University HospitalPhiladelphia, United StatesContact: Yedidya Saiman (principal investigator)Taking people
- Mayo ClinicPhoenix, United StatesContact: Hugo Vargas (principal investigator)Taking people
- St. Joseph's Hospital and Medical CenterPhoenix, United StatesContact: Nilofar Najafian (principal investigator)Taking people
- Bon Secours St. Mary's HospitalRichmond, United StatesContact: Mitchell Shiffman (principal investigator)Taking people
- VCU Medical Center North HospitalRichmond, United StatesContact: Amon Asgharpour (principal investigator)Taking people
- Mayo Clinic - PPDSRochester, United StatesContact: Harmeet Malhi (principal investigator)Taking people
- The Texas Liver InstituteSan Antonio, United StatesContact: Eric Lawitz (principal investigator)Taking people
- University of California Benioff Children's HospitalSan Francisco, United StatesContact: Philip Rosenthal (principal investigator)Taking people
- Cardinal Glennon Children's HospitalSt Louis, United StatesContact: Jeffery Teckman (principal investigator)Taking people
- Washington University School of Medicine in St. LouisSt Louis, United StatesContact: Scott McHenry (principal investigator)Taking people
- University of Arizona Thomas D. Boyer Liver InstituteTucson, United StatesNo longer taking part
About the trial
What the trial wants to find out
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo.
Read full original descriptionShow less
Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.
The 2 groups in the trial
- FazirsiranTreatment being tested
Participants will receive fazirsiran 200 milligram per milliliter (mg/ml) subcutaneous (SC) injection on Day 1, at Week 4, and then every 12 weeks (Q12 W) thereafter up to Week 196.
Treatment: Fazirsiran Injection
- PlaceboPlacebo, for comparison
Participants will receive placebo on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
- Fit questions
- Built from NCT05677971, who can take part
- Record updated
- 13 May 2026